Antihypertensive treatment and regression of atherosclerosis

Area of Science:

• Cardiovascular Pharmacology
• Atherosclerosis Research

Background:

• Blood pressure reduction's impact on coronary outcomes is less than anticipated.
• Antihypertensive medications may have varying anti-atherogenic capacities.

Purpose of the Study:

• To explore the anti-atherogenic potential of different classes of antihypertensive drugs.
• To analyze the mechanisms behind these anti-atherogenic properties.

Main Methods:

• Review of experimental and clinical evidence for calcium antagonists, beta-blockers, and ACE inhibitors.
• Analysis of data from trials like INTACT and ongoing investigations like the PACK trial.

Main Results:

• Calcium antagonists (e.g., nifedipine) showed evidence of reducing aortic lipid deposition and delaying atherosclerotic lesions.
• ACE inhibitors demonstrated anti-atherogenic effects in animal models.
• Beta-blockers may possess anti-atherogenic properties despite effects on atherogenic lipid fractions.
• Ketanserine (serotonin antagonist) is under investigation for anti-atherogenic capacity.

Conclusions:

• Antihypertensive drugs exhibit diverse anti-atherogenic properties beyond blood pressure lowering.
• These properties may contribute to improved cardiovascular outcomes.
• Further research, including trials like PACK, is crucial to confirm these effects.